Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2022

View Archived Issues

Study shows disease-linked DNA variants are active at different stages of T-cell activation

Pendrin inhibitor ARBM-201 reduces lung injury in acute respiratory distress syndrome model

NLRP3 inflammasome inhibitor INF-176 for the treatment of Alzheimer's disease

MAb-loaded extracellular vesicles show potential as cancer therapeutics

Shanghai Yao Biotech discloses new TRK inhibitors

Sichuan Haisco Pharmaceutical patents ENPP2 inhibitors

Tyligand Bioscience divulges GTPase KRAS mutant inhibitors

Betta Pharmaceuticals identifies new IDH inhibitors

Broadenbio synthesizes new MAP4K1 inhibitors

Morc2 S87L mutation in mice mimics human Charcot-Marie-Tooth disease

TrxR inhibitor Au-24 shows promise in vivo and in vitro for treating hepatocellular carcinoma

Atux Iskay presents preclinical data on PP2A activator ATUX-792 in IPF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...